Andrej Karpathy, the former Tesla AI director and OpenAI cofounder, is calling a recent Python package attack "software horror"—and the details are genuinely alarming. A compromised version of LiteLLM ...

Hotel loyalty programs have long promised travelers something alluring. Stay enough nights and eventually the perks will follow. Free stays, upgrades, late checkout, maybe even a lounge with ...

The college, which is part of the Mormon church’s educational system, was approved to offer three-year degrees two and a half years ago. Now, all 10 of its majors will be available in a reduced-credit ...

Section 1. Purpose and Policy. Buying and owning a home has long been considered the pinnacle of the American dream and a way for families to invest and build lifetime wealth. But because of the ...

Loyalty programs remain a powerful tool for businesses. According to last year’s Statista survey, a third of marketers believe their company earns five to seven times more from these programs than it ...

The top college football teams in the country are built in the trenches. What good is an elite quarterback or running back without a top offensive line to block for them? It all starts upfront. That's ...

AI-driven forecasting only delivers real business value when organizations rigorously measure forecast value add (FVA) to ensure every model, agent, and… The future of forecast value add: An expert’s ...

Homeowners in parts of western Washington whose properties were damaged or destroyed by this month’s historic flooding may have the option to sell their homes to local governments through voluntary ...

(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...

– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...